HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paul H A Quax Selected Research

Toll-Like Receptor 4

1/2015RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner.
1/2014Toll-like receptor 4 inhibitor TAK-242 treatment does not influence perfusion recovery in tissue ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paul H A Quax Research Topics

Disease

29Atherosclerosis
11/2022 - 05/2006
22Ischemia
06/2022 - 07/2004
19Inflammation (Inflammations)
01/2022 - 03/2005
12Atherosclerotic Plaque (Atheroma)
12/2021 - 01/2012
12Neointima
01/2020 - 05/2002
10Vascular Remodeling
11/2023 - 04/2010
10Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 09/2007
8Hyperplasia
01/2020 - 05/2002
7Pathologic Constriction (Stenosis)
01/2022 - 12/2005
6Thrombosis (Thrombus)
01/2021 - 03/2003
5Hypoxia (Hypoxemia)
01/2024 - 04/2013
5Neoplasms (Cancer)
04/2021 - 10/2005
5Infarction (Infarctions)
01/2021 - 01/2018
4Rupture
11/2022 - 01/2012
4Hemorrhage
11/2022 - 05/2013
4Arteriovenous Fistula
10/2022 - 01/2016
4Myocardial Ischemia (Ischemic Heart Diseases)
12/2020 - 01/2018
4Reperfusion Injury
12/2020 - 01/2018
4Abdominal Aortic Aneurysm
01/2018 - 04/2004
3Ischemic Stroke
11/2023 - 11/2015
3Chronic Limb-Threatening Ischemia
09/2023 - 01/2018
3Heart Failure
10/2022 - 08/2019
3Central Serous Chorioretinopathy
01/2022 - 11/2018
3Myocardial Infarction
04/2021 - 09/2011
3Carotid Stenosis (Carotid Artery Stenosis)
12/2019 - 12/2013
3Coronary Disease (Coronary Heart Disease)
02/2012 - 09/2005
3Vascular System Injuries
01/2011 - 05/2002
2Stroke (Strokes)
11/2023 - 12/2020
2Coronary Artery Disease (Coronary Atherosclerosis)
01/2016 - 01/2015
2Arterial Occlusive Diseases (Arterial Occlusive Disease)
03/2014 - 07/2004
1Intraoperative Complications
11/2023
1Hemorrhagic Stroke
11/2023

Drug/Important Bio-Agent (IBA)

18MicroRNAs (MicroRNA)IBA
11/2023 - 08/2009
13Apolipoproteins E (ApoE)IBA
01/2022 - 08/2007
8Apolipoprotein E3IBA
10/2022 - 08/2010
6Biomarkers (Surrogate Marker)IBA
11/2023 - 02/2012
4Phosphorylcholine (Phosphocholine)IBA
11/2022 - 04/2020
4CholesterolIBA
01/2020 - 01/2017
3Proteins (Proteins, Gene)FDA Link
11/2023 - 02/2010
3AntibodiesIBA
11/2022 - 12/2020
3Adenosine (Adenocard)FDA LinkGeneric
10/2022 - 01/2018
3InosineFDA Link
10/2022 - 01/2018
3Messenger RNA (mRNA)IBA
01/2022 - 12/2005
3ApolipoproteinsIBA
10/2020 - 07/2009
3Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2020 - 12/2002
3LipidsIBA
01/2020 - 08/2013
3Interleukin-10 (Interleukin 10)IBA
01/2018 - 08/2007
3Phenobarbital (Luminal)FDA Link
01/2017 - 08/2012
3Small Interfering RNA (siRNA)IBA
01/2014 - 07/2009
3CytokinesIBA
04/2013 - 04/2010
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2011 - 05/2005
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2007 - 12/2002
2Peptides (Polypeptides)IBA
11/2023 - 06/2018
2Small Nucleolar RNA (snoRNA)IBA
12/2022 - 08/2019
2oxidized low density lipoproteinIBA
11/2022 - 01/2014
2Hydrocortisone (Cortisol)FDA LinkGeneric
01/2022 - 01/2022
2Toll-Like Receptors (Toll-Like Receptor)IBA
01/2022 - 08/2012
2Antisense OligonucleotidesIBA
12/2021 - 12/2019
2matrigelIBA
08/2021 - 01/2020
2EndoglinIBA
04/2021 - 02/2021
2Immunoglobulin G (IgG)IBA
12/2020 - 01/2014
2Hydrogen Sulfide (Sulfide, Hydrogen)IBA
11/2020 - 01/2020
2Immunoglobulin E (IgE)IBA
01/2019 - 01/2014
2Annexin A5IBA
01/2018 - 01/2011
2Complementary DNA (cDNA)IBA
01/2018 - 08/2007
2ChemokinesIBA
03/2017 - 08/2015
2garcinolIBA
01/2017 - 08/2013
2Lysine AcetyltransferasesIBA
01/2017 - 01/2011
2Toll-Like Receptor 4IBA
01/2015 - 01/2014
2Complement System Proteins (Complement)IBA
10/2014 - 02/2013
2Matrix Metalloproteinases (MMPs)IBA
01/2012 - 10/2005
2Tissue Inhibitor of Metalloproteinase-1IBA
01/2012 - 02/2010
2PolymersIBA
08/2011 - 12/2005
2Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2011 - 07/2010
2Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2011 - 02/2010
2LipopolysaccharidesIBA
08/2010 - 10/2002
2Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric
08/2010 - 01/2007
2Dexamethasone (Maxidex)FDA LinkGeneric
04/2006 - 12/2005
2CollagenIBA
12/2005 - 04/2004
2Tissue Inhibitor of Metalloproteinase-3IBA
10/2005 - 05/2005
1Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
01/2024
1Methionine (L-Methionine)FDA Link
11/2023
1Calcium-Binding ProteinsIBA
11/2023
1AutoantibodiesIBA
11/2023
1N-Methylaspartate (NMDA)IBA
11/2023
1Glial Fibrillary Acidic ProteinIBA
11/2023
1Untranslated RNA (Noncoding RNA)IBA
11/2023
1Leu Transfer RNAIBA
12/2022
1Monoclonal AntibodiesIBA
11/2022

Therapy/Procedure

18Therapeutics
09/2023 - 07/2004
4Percutaneous Coronary Intervention
10/2020 - 12/2005
4Stents
08/2011 - 04/2004
3Endarterectomy (Thromboendarterectomy)
01/2021 - 11/2015
3Ligation
10/2020 - 01/2004
2Renal Dialysis (Hemodialysis)
10/2022 - 01/2016
2Lasers (Laser)
11/2021 - 01/2014
2Operative Surgical Procedures
07/2019 - 02/2016
2Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2016 - 06/2006
2Drug-Eluting Stents
05/2006 - 03/2005
1Vascular Surgical Procedures
11/2023